BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $10.28 billion. The enterprise value is $9.57 billion.
| Market Cap | 10.28B |
| Enterprise Value | 9.57B |
Important Dates
The last earnings date was Monday, May 4, 2026, after market close.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 193.27 million shares outstanding. The number of shares has increased by 0.86% in one year.
| Current Share Class | 193.27M |
| Shares Outstanding | 193.27M |
| Shares Change (YoY) | +0.86% |
| Shares Change (QoQ) | +2.83% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 97.07% |
| Float | 192.16M |
Valuation Ratios
The trailing PE ratio is 37.94 and the forward PE ratio is 9.47. BMRN's PEG ratio is 0.33.
| PE Ratio | 37.94 |
| Forward PE | 9.47 |
| PS Ratio | 3.19 |
| Forward PS | 2.57 |
| PB Ratio | 1.67 |
| P/TBV Ratio | 1.78 |
| P/FCF Ratio | 13.49 |
| P/OCF Ratio | 11.84 |
| PEG Ratio | 0.33 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.15, with an EV/FCF ratio of 12.47.
| EV / Earnings | 35.60 |
| EV / Sales | 2.95 |
| EV / EBITDA | 15.15 |
| EV / EBIT | 16.94 |
| EV / FCF | 12.47 |
Financial Position
The company has a current ratio of 5.81, with a Debt / Equity ratio of 0.23.
| Current Ratio | 5.81 |
| Quick Ratio | 3.94 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 2.24 |
| Debt / FCF | 1.88 |
| Interest Coverage | 24.56 |
Financial Efficiency
Return on equity (ROE) is 4.48% and return on invested capital (ROIC) is 7.43%.
| Return on Equity (ROE) | 4.48% |
| Return on Assets (ROA) | 4.49% |
| Return on Invested Capital (ROIC) | 7.43% |
| Return on Capital Employed (ROCE) | 7.24% |
| Weighted Average Cost of Capital (WACC) | 4.97% |
| Revenue Per Employee | $1.01M |
| Profits Per Employee | $83,434 |
| Employee Count | 3,221 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 1.24 |
Taxes
In the past 12 months, BMRN has paid $116.85 million in taxes.
| Income Tax | 116.85M |
| Effective Tax Rate | 30.30% |
Stock Price Statistics
The stock price has decreased by -11.17% in the last 52 weeks. The beta is 0.23, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | -11.17% |
| 50-Day Moving Average | 55.52 |
| 200-Day Moving Average | 56.15 |
| Relative Strength Index (RSI) | 43.57 |
| Average Volume (20 Days) | 1,756,808 |
Short Selling Information
The latest short interest is 10.79 million, so 5.58% of the outstanding shares have been sold short.
| Short Interest | 10.79M |
| Short Previous Month | 10.15M |
| Short % of Shares Out | 5.58% |
| Short % of Float | 5.62% |
| Short Ratio (days to cover) | 5.38 |
Income Statement
In the last 12 months, BMRN had revenue of $3.24 billion and earned $268.74 million in profits. Earnings per share was $1.40.
| Revenue | 3.24B |
| Gross Profit | 1.66B |
| Operating Income | 564.79M |
| Pretax Income | 385.59M |
| Net Income | 268.74M |
| EBITDA | 631.29M |
| EBIT | 564.79M |
| Earnings Per Share (EPS) | $1.40 |
Balance Sheet
The company has $2.22 billion in cash and $1.44 billion in debt, with a net cash position of $782.83 million or $4.05 per share.
| Cash & Cash Equivalents | 2.22B |
| Total Debt | 1.44B |
| Net Cash | 782.83M |
| Net Cash Per Share | $4.05 |
| Equity (Book Value) | 6.21B |
| Book Value Per Share | 32.14 |
| Working Capital | 3.81B |
Cash Flow
In the last 12 months, operating cash flow was $874.25 million and capital expenditures -$107.19 million, giving a free cash flow of $767.06 million.
| Operating Cash Flow | 874.25M |
| Capital Expenditures | -107.19M |
| Depreciation & Amortization | 66.50M |
| Net Borrowing | 850.00M |
| Free Cash Flow | 767.06M |
| FCF Per Share | $3.97 |
Margins
Gross margin is 51.16%, with operating and profit margins of 17.42% and 8.29%.
| Gross Margin | 51.16% |
| Operating Margin | 17.42% |
| Pretax Margin | 11.89% |
| Profit Margin | 8.29% |
| EBITDA Margin | 19.47% |
| EBIT Margin | 17.42% |
| FCF Margin | 23.66% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.86% |
| Shareholder Yield | -0.86% |
| Earnings Yield | 2.60% |
| FCF Yield | 7.41% |
Analyst Forecast
The average price target for BMRN is $88.53, which is 66.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $88.53 |
| Price Target Difference | 66.44% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 9.07% |
| EPS Growth Forecast (5Y) | 26.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 3.94 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.94 |
| Piotroski F-Score | 5 |